尿激酶型纖溶酶原激活因子受體(uPAR)重組蛋白
Recombinant Plasminogen Activator, Urokinase Receptor (uPAR)
CD87; PLAUR; PLAU-R; U-PAR; URKR; Monocyte Activation Antigen Mo3
- 編號RPA141Hu03
- 物種Homo sapiens (Human，人)相同的名稱，不同的物種。
- 來源原核表達
- 宿主E.coli
- 內(nèi)毒素水平<1.0EU/µg(LAL法測定)
- 亞細胞定位細胞膜, 分泌
- 預測分子量39.2kDa
- 實際分子量39&33&30&26kDa(差異分析請參閱說明書)
- 片段與標簽Gly221~Gly305 with N-terminal His and GST Tag
- 緩沖液成份PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
- 性狀凍干粉
- 純度> 80%
- 等電點6.5
- 應用Positive Control; Immunogen; SDS-PAGE; WB.
如果需要有生物活性的蛋白，請參見活性蛋白。 - 下載英文說明書 中文說明書
- 規(guī)格10μg50μg200μg1mg5mg
- 價格¥ 768¥ 1920¥ 3840¥ 11520¥ 28800
- 欲了解實際交易價格和更多情況，請與當?shù)亟?jīng)銷商聯(lián)系!
產(chǎn)品包裝(模擬)
產(chǎn)品包裝(模擬)
Figure. SDS-PAGE
通過ISO 9001、ISO 13485質(zhì)量體系認證
序列
用法
Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲存
避免反復凍融。2-8°C不超過一個月，-80°C不超過12個月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定，具體方法如下：在37°C孵育48小時，沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當?shù)臈l件下存儲，損失率低于5%。
增值服務
相關產(chǎn)品
| 編號 | 適用物種：Homo sapiens (Human，人) | 應用(僅供研究使用，不用于臨床診斷！) |
| RPA141Hu01 | 尿激酶型纖溶酶原激活因子受體(uPAR)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPA141Hu02 | 尿激酶型纖溶酶原激活因子受體(uPAR)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| APA141Hu04 | 尿激酶型纖溶酶原激活因子受體(uPAR)活性蛋白 | Cell?culture;?Activity?Assays. |
| RPA141Hu04 | 尿激酶型纖溶酶原激活因子受體(uPAR)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPA141Hu03 | 尿激酶型纖溶酶原激活因子受體(uPAR)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAA141Hu04 | 尿激酶型纖溶酶原激活因子受體(uPAR)多克隆抗體 | WB |
| PAA141Hu01 | 尿激酶型纖溶酶原激活因子受體(uPAR)多克隆抗體 | WB; IHC |
| PAA141Hu02 | 尿激酶型纖溶酶原激活因子受體(uPAR)多克隆抗體 | WB |
| PAA141Hu03 | 尿激酶型纖溶酶原激活因子受體(uPAR)多克隆抗體 | WB; IHC; ICC; IP. |
| LAA141Hu71 | 尿激酶型纖溶酶原激活因子受體(uPAR)多克隆抗體(生物素標記) | WB; IHC; ICC. |
| LAA141Hu83 | 尿激酶型纖溶酶原激活因子受體(uPAR)多克隆抗體(異硫氰酸熒光素標記) | WB; IHC; ICC; IF. |
| LAA141Hu81 | 尿激酶型纖溶酶原激活因子受體(uPAR)多克隆抗體(異硫氰酸熒光素標記) | WB; IHC; ICC; IF. |
| FAA141Hu81 | 抗尿激酶型纖溶酶原激活因子受體(uPAR)多克隆抗體(異硫氰酸熒光素標記) | FCM |
| MAA141Hu22 | 尿激酶型纖溶酶原激活因子受體(uPAR)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA141Hu21 | 尿激酶型纖溶酶原激活因子受體(uPAR)單克隆抗體 | WB |
| LAA141Hu82 | 尿激酶型纖溶酶原激活因子受體(uPAR)單克隆抗體(異硫氰酸熒光素標記) | WB; IHC; ICC; IF. |
| SEA141Hu | 尿激酶型纖溶酶原激活因子受體(uPAR)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMA141Hu | 尿激酶型纖溶酶原激活因子受體(uPAR)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻
| 雜志 | 參考文獻 |
| International Journal of Cancer | Dietary supplementation with methylseleninic acid, but not selenomethionine, reduces spontaneous metastasis of Lewis lung carcinoma in mice[Wiley: source] |
| Biomark Insights | Decreased Epidermal Growth Factor (EGF) Associated with HMGB1 and Increased Hyperactivity in Children with Autism[PubMed: PMC3623607] |
| Biomarker insights | Decreased Hepatocyte Growth Factor (HGF) and Gamma Aminobutyric Acid (GABA) in Individuals with Obsessive-Compulsive Disorder (OCD)[PubMed: PMC3762604] |
| Am J Emerg Med | Clinical value of soluble urokinase-type plasminogen activator receptor in the diagnosis, prognosis, and therapeutic guidance of sepsis[PubMed: 26615223] |
| Archives of Clinical Infectious Diseases | Evaluation of Diagnostic Value of Soluble Urokinase-Type Plasminogen Activator Receptor in Sepsis[Archcid: 26346] |
| The American Journal of Emergency Medicine | Clinical value of soluble urokinase-type plasminogen activator receptor in the diagnosis, prognosis, and therapeutic Cavia (Guinea pig )idance of sepsis[science:S0735675715009559] |
| Journal of Clinical and Experimental Hepatology | Evaluation of Plasma Urokinase-Type Plasminogen Activator Receptor (UPAR) in Patients With Chronic Hepatitis B, C and Non-Alcoholic Fatty Liver Disease (NAFLD)?…[10.1016:j.jceh.2018.02.001] |
| Turkish journal of trauma & emergency surgery | The diagnostic value of serum urokinase-type plasminogen activator receptor in acute appendicitis[Pubmed: 31475329] |
| CELL TRANSPLANTATION | Predictive Value of Degranulating Factors of Neutrophils in Massive Cerebral Infarction[33787356] |